Chardan Capital no longer expects underperformance from Orexigen (Nasdaq: OREX), according to a report issued earlier Monday. The updated ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE